Stockwinners Market Radar for January 03, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:39 EST Xpeng announces vehicle delivery results for December 2020 - Xpeng announced its vehicle delivery results for December 2020, the fourth quarter and year-ended December 31, 2020. Xpeng achieved a record monthly delivery of 5,700 Smart EVs in December 2020, consisting of a record high 3,691 P7s, the company's sports smart sedan, and 2,009 G3s, its smart compact SUV. The company's December deliveries represent a 326% increase year-over-year and a 35% increase from November. The company delivered a total of 12,964 Smart EVs in the fourth quarter of 2020, a record quarterly delivery representing a 303% increase year-over-year and 51% increase from the third quarter of 2020. In the fourth quarter 2020, 8,527 P7s were delivered. Total deliveries for the year ended December 31, 2020, reached 27,041 units, representing a 112% increase year-over-year. Cumulative P7 deliveries for the year reached 15,062 with mass delivery beginning at the end of June. A total of 11,979 G3s were delivered in 2020.

20:10 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Tesla (TSLA) said on Saturday that it delivered 180,570 electric vehicles in the fourth quarter and produced 179,757 vehicles total. The carmaker also said it delivered 499,550 in 2020 versus its recent guidance of 500,000 vehicles, and produced 509,737 total. In the fourth quarter, Tesla delivered 18,920 and produced 16,670 Model S/X vehicles, and delivered 161,650 and produced 163,660 Model 3/Y vehicles. Additionally, the company announced that it delivered 57,039 and produced 54,850 Model S/X vehicles in 2020, and delivered 442,511 and produced 454,932 Model 3/Y vehicles this year. 2. The U.S. government is considering giving some people half the dose of Moderna's (MRNA) COVID-19 vaccine in order to speed vaccinations, Reuters' Brendan Pierson reported, citing a federal official. "We know that for the Moderna vaccine, giving half of the dose to people between the ages of 18 and 55, two doses, half the dose, which means exactly achieving the objective of immunizing double the number of people with the doses we have," Moncef Slaoui, head of Operation Warp Speed, said. "We know it induces identical immune response" to the full dose, he added. 3. Nordstrom (JWN), aided by reduced competition and its investments in online capabilities, looks not only like a survivor, but possibly a long-term winner, Teresa Rivas wrote in this week's edition of Barron's. While its stock has more than doubled off its low, it's still some 40% below its February high, the author noted, adding that she wouldn't be surprised if Nordstrom closes that gap. 4. Nancy Pelosi was narrowly re-elected speaker of the U.S. House of Representatives on Sunday, as a new Congress took office amid political uncertainty, with Senate control undecided and a Republican fight looming over presidential election results, Reuters' Susan Cornwell reported. 5. Bank of America (BAC), Coca-Cola (KO), CVS (CVS), Liberty Braves (BATRK), MSG Sports (MSGS), Sysco (SYY) and Disney (DIS) saw positive mentions in this week's edition of Barron's.

15:58 EST Bristol-Myers provides update on status of Contingent Value Rights - Bristol Myers Squibb announced that the Biologics License Application for lisocabtagene maraleucel for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies remains under review by the U.S. Food and Drug Administration and the company has not received a decision. As previously announced, the FDA has not provided a new action date for this application. Bristol Myers Squibb continues to work closely with the FDA to support the ongoing review of the BLA for liso-cel and is committed to bringing this therapy to patients. Since the FDA approval of liso-cel did not occur by December 31, 2020, one of the three required milestones for payment of the Bristol Myers Squibb Contingent Value Right was not met. As a result, on January 1, 2021, the Contingent Value Rights Agreement, pursuant to which the CVRs were issued, terminated automatically in accordance with its terms and the CVRs are no longer eligible for payment under the CVR Agreement. The CVRs will no longer trade on the NYSE.

15:43 EST Li Auto provides December 2020 delivery update - Li Auto announced that the company delivered 6,126 Li ONEs in December 2020, representing an increase of 31.9% month-over-month and 529.6% year-over-year. The company's deliveries for the fourth quarter reached 14,464, 67% higher than those for the third quarter and 20.5% above the top end of the company's guidance. Li Auto also noted that the number of Li ONE orders for December was at its highest level ever. Additionally, cumulative deliveries of Li ONEs exceeded 30,000 as of December 18, 2020.